Exposure-response competing risk analysis of GF, mortality, and aGVHD. Based on the median concentration at the day of transplant (0.77 μg/mL), patients were stratified into the high-exposure group (>0.77 μg/mL, represented in red) or into the low-exposure group (≤0.77 μg/mL, represented in blue). (A) Overall cumulative incidence of GF (second HSCT, green line) accounting for death as competing risk (yellow line). (B) Cumulative incidence of GF (second HSCT) in correlation with alemtuzumab exposure. (C) Overall cumulative incidence of mortality (yellow line) accounting for GF (second HSCT, green line) as competing risk. (D) Cumulative incidence of mortality in correlation with alemtuzumab exposure. (E) Overall cumulative incidence of aGVHD (purple line) accounting for GF (second HSCT, green line) and death (yellow line) as competing risks. (F) Cumulative incidence of aGVHD in correlation with alemtuzumab exposure.